BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 36922305)

  • 1. Tailored axillary surgery - A novel concept for clinically node positive breast cancer.
    Heidinger M; Knauer M; Tausch C; Weber WP
    Breast; 2023 Jun; 69():281-289. PubMed ID: 36922305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial.
    Henke G; Knauer M; Ribi K; Hayoz S; Gérard MA; Ruhstaller T; Zwahlen DR; Muenst S; Ackerknecht M; Hawle H; Fitzal F; Gnant M; Mátrai Z; Ballardini B; Gyr A; Kurzeder C; Weber WP
    Trials; 2018 Dec; 19(1):667. PubMed ID: 30514362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tailored axillary surgery in patients with clinically node-positive breast cancer: Pre-planned feasibility substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101).
    Weber WP; Matrai Z; Hayoz S; Tausch C; Henke G; Zwahlen DR; Gruber G; Zimmermann F; Seiler S; Maddox C; Ruhstaller T; Muenst S; Ackerknecht M; Kuemmel S; Bjelic-Radisic V; Kurzeder C; Újhelyi M; Vrieling C; Satler R; Meyer I; Becciolini C; Bucher S; Simonson C; Fehr PM; Gabriel N; Maráz R; Sarlos D; Dedes KJ; Leo C; Berclaz G; Dubsky P; Exner R; Fansa H; Hager C; Reisenberger K; Singer CF; Reitsamer R; Reinisch M; Winkler J; Lam GT; Fehr MK; Naydina T; Kohlik M; Clerc K; Ostapenko V; Fitzal F; Nussbaumer R; Maggi N; Schulz A; Markellou P; Lelièvre L; Egle D; Heil J; Knauer M
    Breast; 2021 Dec; 60():98-110. PubMed ID: 34555676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Imaging-Guided Localization on Performance of Tailored Axillary Surgery in Patients with Clinically Node-Positive Breast Cancer: Prospective Cohort Study Within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101).
    Weber WP; Heidinger M; Hayoz S; Matrai Z; Tausch C; Henke G; Zwahlen DR; Gruber G; Zimmermann F; Montagna G; Andreozzi M; Goldschmidt M; Schulz A; Mueller A; Ackerknecht M; Tampaki EC; Bjelic-Radisic V; Kurzeder C; Sávolt Á; Smanykó V; Hagen D; Müller DJ; Gnant M; Loibl S; Fitzal F; Markellou P; Bekes I; Egle D; Heil J; Knauer M
    Ann Surg Oncol; 2024 Jan; 31(1):344-355. PubMed ID: 37903951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of axillary surgery on outcome of clinically node positive breast cancer treated with neoadjuvant chemotherapy.
    Dux J; Habibi M; Malik H; Jacobs L; Wright PA; Lange J; Camp M; O'Donnell M; Sun B; Tran HT; Euhus D
    Breast Cancer Res Treat; 2023 Nov; 202(2):267-273. PubMed ID: 37531016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Axillary Dissection With Systemic Therapy in Patients With Clinically Node-Positive Breast Cancer.
    Weber WP; Matrai Z; Hayoz S; Tausch C; Henke G; Zimmermann F; Montagna G; Fitzal F; Gnant M; Ruhstaller T; Muenst S; Mueller A; Lelièvre L; Heil J; Knauer M; Egle D; Sávolt Á; Heidinger M; Kurzeder C; ; Zwahlen DR; Gruber G; Ackerknecht M; Kuemmel S; Bjelic-Radisic V; Smanykó V; Vrieling C; Satler R; Hagen D; Becciolini C; Bucher S; Simonson C; Fehr PM; Gabriel N; Maráz R; Sarlos D; Dedes KJ; Leo C; Berclaz G; Fansa H; Hager C; Reisenberger K; Singer CF; Loibl S; Winkler J; Lam GT; Fehr MK; Kohlik M; Clerc K; Ostapenko V; Maggi N; Schulz A; Andreozzi M; Goldschmidt M; Saccilotto R; Markellou P
    JAMA Surg; 2023 Oct; 158(10):1013-1021. PubMed ID: 37466971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Would Removal of All Ultrasound Abnormal Metastatic Lymph Nodes Without Sentinel Lymph Node Biopsy Be Accurate in Patients with Breast Cancer with Neoadjuvant Chemotherapy?
    Lim GH; Gudi M; Teo SY; Ng RP; Yan Z; Lee YS; Allen JC; Leong LCH
    Oncologist; 2020 Nov; 25(11):e1621-e1627. PubMed ID: 32537791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative).
    Ollila DW; Cirrincione CT; Berry DA; Carey LA; Sikov WM; Hudis CA; Winer EP; Golshan M
    J Am Coll Surg; 2017 Apr; 224(4):688-694. PubMed ID: 28089784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Optimal treatment of the axilla after positive sentinel lymph node biopsy in early invasive breast cancer. Early results of the OTOASOR trial].
    Sávolt A; Musonda P; Mátrai Z; Polgár C; Rényi-Vámos F; Rubovszky G; Kovács E; Sinkovics I; Udvarhelyi N; Török K; Kásler M; Péley G
    Orv Hetil; 2013 Dec; 154(49):1934-42. PubMed ID: 24292111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Axillary surgery in node-positive breast cancer.
    Maggi N; Nussbaumer R; Holzer L; Weber WP
    Breast; 2022 Mar; 62 Suppl 1(Suppl 1):S50-S53. PubMed ID: 34511332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility and safety of targeted axillary dissection guided by intraoperative ultrasound after neoadjuvant treatment.
    Siso C; Esgueva A; Rivero J; Morales C; Miranda I; Peg V; Gil-Moreno A; Espinosa-Bravo M; Rubio IT
    Eur J Surg Oncol; 2023 Oct; 49(10):106938. PubMed ID: 37244843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic accuracy of de-escalated surgical procedure in axilla for node-positive breast cancer patients treated with neoadjuvant systemic therapy: A systematic review and meta-analysis.
    Song YX; Xu Z; Liang MX; Liu Z; Hou JC; Chen X; Xu D; Fei YJ; Tang JH
    Cancer Med; 2022 Nov; 11(22):4085-4103. PubMed ID: 35502768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does ultrasound evaluation of the axilla increase the rate of axillary lymph node dissection in early stage clinically node negative breast cancer patients?
    Vasigh M; Meshkati Yazd SM; Karoobi M; Hajebi R; Yazdankhah Kenari A
    BMC Surg; 2022 Mar; 22(1):80. PubMed ID: 35241059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection.
    Caudle AS; Yang WT; Krishnamurthy S; Mittendorf EA; Black DM; Gilcrease MZ; Bedrosian I; Hobbs BP; DeSnyder SM; Hwang RF; Adrada BE; Shaitelman SF; Chavez-MacGregor M; Smith BD; Candelaria RP; Babiera GV; Dogan BE; Santiago L; Hunt KK; Kuerer HM
    J Clin Oncol; 2016 Apr; 34(10):1072-8. PubMed ID: 26811528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical feasibility and oncological safety of non-radioactive targeted axillary dissection after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: a prospective diagnostic and prognostic study.
    Wu SY; Li JW; Wang YJ; Jin KR; Yang BL; Li JJ; Yu XL; Mo M; Hu N; Shao ZM; Liu GY
    Int J Surg; 2023 Jul; 109(7):1863-1870. PubMed ID: 37132193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Axillary lymph node dissection can be omitted in patients with limited clinically node-positive breast cancer: a National Cancer Database analysis.
    Cocco D; Shah C; Wei W; Wilkerson A; Grobmyer SR; Al-Hilli Z
    Br J Surg; 2022 Nov; 109(12):1293-1299. PubMed ID: 36066266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Accuracy of Sentinel Lymph Node Biopsy Alone in Clinically Node-Positive Patients Undergoing Upfront Surgery for Invasive Breast Cancer: A Systematic Review.
    Lovrics O; Tao B; Parvez E
    Curr Oncol; 2023 Mar; 30(3):3102-3110. PubMed ID: 36975448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. False-negative rate in the extended prospective TATTOO trial evaluating targeted axillary dissection by carbon tattooing in clinically node-positive breast cancer patients receiving neoadjuvant systemic therapy.
    de Boniface J; Frisell J; Kühn T; Wiklander-Bråkenhielm I; Dembrower K; Nyman P; Zouzos A; Gerber B; Reimer T; Hartmann S
    Breast Cancer Res Treat; 2022 Jun; 193(3):589-595. PubMed ID: 35451733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. This house believes that: MARI/TAD is better than sentinel node biopsy after PST for cN+ patients.
    van Hemert AKE; van Duijnhoven FH; Vrancken Peeters MTFD
    Breast; 2023 Oct; 71():89-95. PubMed ID: 37562108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocol.
    van Loevezijn AA; van der Noordaa MEM; Stokkel MPM; van Werkhoven ED; Groen EJ; Loo CE; Elkhuizen PHM; Sonke GS; Russell NS; van Duijnhoven FH; Vrancken Peeters MTFD
    Breast Cancer Res Treat; 2022 May; 193(1):37-48. PubMed ID: 35239072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.